share_log

Needham Reiterates Buy on Axsome Therapeutics, Maintains $130 Price Target

Benzinga ·  Nov 12 20:40  · Ratings

Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $130 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment